FJACX
Price
$12.70
Change
+$0.09 (+0.71%)
Updated
Jul 31 closing price
Net Assets
1.96B
VSMAX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

FJACX vs VSMAX

FJACX vs VSMAX Comparison Chart in %
View a ticker or compare two or three
VS
FJACX vs. VSMAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FJACX is a Buy and VSMAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSMAX has more cash in the bank: 189B vs. FJACX (1.96B). VSMAX pays higher dividends than FJACX: VSMAX (1.21) vs FJACX (0.93). FJACX was incepted earlier than VSMAX: FJACX (13 years) vs VSMAX (26 years). VSMAX (0.05) is less costly to investors than FJACX (0.00). FJACX is a more actively managed with annual turnover of: 71.00 vs. VSMAX (17.00). FJACX has a lower initial minimum investment than VSMAX: FJACX (0) vs VSMAX (3000). VSMAX annual gain was more profitable for investors over the last year : 22.58 vs. FJACX (16.04). VSMAX return over 5 years is better than : 35.11 vs. FJACX (-5.54).
FJACXVSMAXFJACX / VSMAX
Total Expense Ratio0.000.05-
Annual Report Gross Expense Ratio0.000.05-
Fund Existence13 years26 years-
Gain YTD15.85114.588109%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.96B189B1%
Annual Yield % from dividends0.931.2177%
Returns for 1 year16.0422.5871%
Returns for 3 years14.2543.4233%
Returns for 5 years-5.5435.11-16%
Returns for 10 years34.05155.9622%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BQLCX23.420.17
+0.73%
Bright Rock Quality Large Cap Instl
GSPQX20.020.12
+0.60%
Goldman Sachs US Eq Div and Premium C
GSIYX24.29N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R6
CCWIX21.73-0.15
-0.69%
Baird Chautauqua International Gr Instl
RYOAX66.89-1.55
-2.26%
Rydex Biotechnology H